Increasing evidence has shown that SPARC is expressed at elevated levels in a variety of cancers, such as mesothelioma [11], haematological malignancies [12], osteosarcoma [13], and gastric carcinomas [14], and this phenotype is associated with a poor prognosis. Here, SPARC is linked to cancer.